Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097170 | 1.00 | CYP2C19 (0.41) | CYP2C19CYP2C9MAPTKMT2AHIF1A | |
| SCHEMBL927772 | 0.94 | CYP2C9 (0.39) | CYP2C19CYP2C9 | |
| SCHEMBL8409146 | 0.94 | CYP2C9 (0.39) | CYP2C19CYP2C9 | |
| SCHEMBL927770 | 0.94 | CYP2C9 (0.39) | CYP2C19CYP2C9 | |
| SCHEMBL12159717 | 0.94 | CYP2C9 (0.39) | CYP2C19CYP2C9 | |
| SCHEMBL14026070 | 0.94 | CYP2C9 (0.39) | CYP2C19CYP2C9 | |
| SCHEMBL8870586 | 0.94 | CYP2C9 (0.39) | CYP2C19CYP2C9 | |
| SCHEMBL15061116 | 0.94 | CYP2C9 (0.39) | CYP2C19CYP2C9 | |
| SCHEMBL22375179 | 0.94 | CYP2C9 (0.39) | CYP2C19CYP2C9 | |
| Water SCHEMBL28276387 | 0.92 | CYP2C9 (0.38) | CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1124828-B1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LAB (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1278747-B1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LAB (US) | 2006-08-23 | — | — | EP | disclosed |
| US-6642222-B2 | Useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions | ABBOTT LABORATORIES | 2003-11-04 | — | — | US | disclosed |
| US-6632418-B2 | Therapy for asthma, sexual disorders, hypotensive agents, analgesics | ABBOTT LABORATORIES | 2003-10-14 | — | — | US | disclosed |
| US-20030065182-A1 | Novel radioligands and their use for identifying potassium channel modulators | ABBOTT LABORATORIES | 2003-04-03 | — | — | US | disclosed |
| US-20030055035-A1 | Pyrano piperidino and thiopyrano compounds and methods of use | ABBOTT LABORATORIES | 2003-03-20 | — | — | US | disclosed |
| WO-2003011869-A1 | RADIOLIGANDS AND THEIR USE FOR IDENTIFYING POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2003-02-13 | — | — | WO | disclosed |
| EP-1278746-A2 | DIHYDROPYRIDINE COMPOUNDS AND METHODS OF USE | Abbott Laboratories (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-1278747-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | Abbott Laboratories (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001083484-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001083480-A2 | DIHYDROPYRIDINE COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-11-08 | — | — | WO | disclosed |
| EP-1131322-A2 | DIHYDROPYRIDINE COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1124828-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| US-6191140-B1 | POTASSIUM CHANNEL MODULATORS; MUSCLE RELAXANTS; CONTROLLING CELL MEMBRANES | ABBOTT LABORATORIES | 2001-02-20 | — | — | US | disclosed |
| WO-2000024741-A2 | DIHYDROPYRIDINE COMPOUNDS AND THEIR USE AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-2000024743-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055035-A1 | Pyrano piperidino and thiopyrano compounds and methods of use | KCNJ3, KCNJ6, KCNJ5 | CYP2C19 1299/4885CYP2C9 1792/4885MAPT 4663/4885 |
| US-20030065182-A1 | Novel radioligands and their use for identifying potassium channel modulators | KCNN3, KCNN1, KCNN2 | CYP2C19 2795/4885CYP2C9 2915/4885MAPT 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.